Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L)

Human Gene Therapy

Volumn 10, Issue 7, 1999, Pages 1095-1103

  Lorenz, Matthias G O ^a   Kantor, Judith A ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD70 ANTIGEN; TUMOR CELL VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADENOCARCINOMA; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD70; CANCER VACCINES; COLONIC NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 0033134720     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018094     Document Type: Article

References (39)

1. AKAGI, J., HODGE, J.W., MCLAUGHLIN, J.P., GRITZ. L., PANICALI, D., KUFE, D., SCHLOM, J., and KANTOR, J. (1997). Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother. 20, 38-47.
2. BLANKENSTEIN, T. (1998). Cancer vaccines: Prospects and problems. Br. J. Cancer 78, 143.
3. BOWMAN, M.R., CRIMMINS, M.A., YETZ-ALDAPE, J., KRIZ, R., KELLEHER, K., and HERRMANN, S. (1994). The cloning of CD70 and its identification us the ligand for CD27. J. Immunol. 152, 1756-1761.
4. CAVALLO, F., MARTIN-FONTECHA, A., BELLONE, M., HELTAI, S., GATTI, E., TORNAGHI, P., FRESCHI, M., FORNI, G., DELLABONA, P., and CASORATI, G. (1995). Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25, 1154-1162.
5. CHEN, L.P., ASHE, S., BRADY, W.A., HELLSTROM, I., HELLSTROM, K.E., LEDBETTER, S.A., MCGOWAN, P., and LINSKY, P.S. (1992). Costimulation of antitumor immunity by the B7 counter-receptor for the lymphocyte-T molecules CD28 and CTLA-4. Cell 71, 1093-1102.
6. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTROM, I., and HELLSTROM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
7. CORBETT, T.H., GRISWOLD, D.P., JR., ROBERTS, B.J., PECKHAM, J.C., and SCHABEL, F.M., JR. (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35, 2434-2439.
8. COUDERC, B., ZITVOGEL, L., DOUIN-ECHINARD, V., DJENNANE, L., TAHARA, H., FAVRE, G., LOTZE, M.T., and ROBBINS, P.D. (1998). Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 5, 163-175.
9. DALGLEISH, A.G. (1996). Co-stimulatory molecules and their role in tumor immunity. In Tumor Immunology: Immunotherapy and Cancer Vaccines. B. Dalgleish, ed. (Cambridge University Press, New York) pp. 185-198.
10. EARL, P.L., and MOSS, B. (1993). Generation of recombinant vaccinia viruses. In Current Protocols in Molecular Biology. F.M. Ausubel, R. Brent, R.E. Kingston, D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl, eds. (John Wiley & Sons, New York) pp. 16.17.11-16.18.10.
11. FOX, B.A., SPIESS, P.J., KASID, A., PURI, R., MULE, J.J., WEBER, J.S., and ROSENBERG, S.A. (1990). In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Modif. 9, 499-511.
12. GOODWIN, R.G., ALDERSON, M.R., SMITH, C.A., ARMITAGE, R.J., VANDENBOS, T., JERZY, R., TOUGH, T.W., SCHOENBORN, M.A., DAVIS-SMITH, T., and HENNEN, K. (1993). Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73, 447-456.
13. GRAVESTEIN, L.A., NIELAND, J.D., KRUISBEEK, A.M., and BORST, J. (1995). Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int. Immunol. 7, 551-557.
14. HINTZEN, R.Q., DE JONG, R., LENS, S.M., and VAN LIER, R.A. (1994). CD27: Marker and mediator of T-cell activation? Immunol. Today 15, 307-311.
15. HINTZEN, R.Q., LENS, S.M., LAMMERS, K., KUIPER, H., BECKMANN, M.P., and VAN LIER, R.A. (1995). Engagement of CD27 with its ligand CD70 provides a second signal for T-cell activation. J. Immunol. 154, 2612-2623.
16. HODGE, J.W., ABRAMS, S., SCHLOM, J., and KANTOR, J.A. (1994). Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54, 5552-5555.
17. HODGE, J.W., MCLAUGHLIN, J.P., ABRAMS, S.I., SHUPERT, W.L., SCHLOM, J., and KANTOR, J.A. (1995). Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55, 3598-3603.
18. KALUS, R.M., KANTOR, J.A., GRITZ, L., YAFAL, A.G., MAZZARA, G.P., SCHLOM, J., and HODGE, J.W. (1999). The use of combination vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 17, 893-903.
19. KANTOR, J., IRVINE, K., ABRAMS, S., SNOY, P., OLSEN, R., GREINER, J., KAUFMAN, H., EGGENSPERGER, D., and SCHLOM, J. (1992). Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 52, 6917-6925.
20. KOBATA, T., AGEMATSU, K., KAMEOKA, J., SCHLOSSMAN, S.F., and MORIMOTO, C. (1994). CD27 is a signal-transducing molecule involved in CD45RA+ native T-cell costimulation. J. Immunol. 153, 5422-5432.
21. LORENZ, M.G.O., KANTOR, J.A., SCHLOM, J., and HODGE, J.W. (1999). Induction of antitumor immunity elicited by recombinant vaccinia virus expressing murine leukocyte function associated antigen-3 (LFA-3). Hum. Gene Ther. 10, 623-631.
22. LI, Y., HELLSTROM, K.E., NEWBY, S.A., and CHEN, L. (1996). Costimulution by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183, 639-644.
23. NAKAJIMA, A., KODAMA, T., MORIMOTO, S., AZUMA, M., TAKEDA, K., OSHIMA, H., YOSHINO, S., YAGITA, H., and OKUMURA, K. (1998). Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161, 1901-1907.
24. NIELAND, J.D., GRAUS, Y.F., DORTMANS, Y.E., KREMERS, B.L., and KRUISBEEK, A.M. (1998). CD40 and CD70 co-stimulate a potent in vivo antitumor T-cell response. J. Immunother. 21, 225-236.
25. OSHIMA, H., NAKANO, H., NOHARA, C., KOBATA, T., NAKAJIMA, A., JENKINS, N.A., GILBERT, D.J., COPELAND, N.G., MUTO, T., YAGITA, H., and OKUMURA, K. (1998). Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol. 10, 517-526.
26. OSTRAND-ROSENBERG, S. (1994). Tumor immunotherapy: The tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6, 722-727.
27. PARDOLL, D.M. (1998). Cancer vaccines. Nature Med. 4, 525-531.
28. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T-cell costimulation by B7/BB1 induces CD8 T-cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
29. ROBBINS, P.F., KANTOR, J.A., SALGALLER, M., HAND, P.H., FERNSTEN, P.D., and SCHLOM, J. (1991). Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51, 3657-3662.
30. ROBEY, E., and ALLISON, J.P. (1995). T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules. Immunol. Today 16, 306-310.
31. SCHWARTZ, R.H. (1996). Models of T-cell anergy: Is there a common molecular mechanism. J. Exp. Med. 184, 1-8.
32. SUNDER-PLASSMANN, R., PICKL, W.F., MAJDIC, O., KNAPP, W., and HOLTER, W. (1995). Crosslinking of CD27 in the presence of CD28 costimulation results in T-cell proliferation and cytokine production. Cell. Immunol. 164, 20-27.
33. TESSELAAR, K., GRAVESTEIN, L.A., VAN SCHIJNDEL, G.M., BORST, J., and VAN LIER, R. A. (1997). Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J. Immunol. 159, 4959-4965.
34. TINE, J.A., LANAR, D.E., SMITH, D.M., WELLDE, B.T., SCHULTHEISS, P., WARE, L.A., KAUFFMAN, E.B., WIRTZ, R.A., DETAISNE, C., HUI, G.S.H., CHNG, S.P., CHURCH, P., HOLLINGDALE, M.R., KASLOW, D.C., HOFFMAN, S., GUITO, K.P., BALLOU, W.R., SADOFF, J.C., and PAOLETTI, E. (1996). NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64, 3833-3844.
35. TOWNSEND, S.E., SU, F.W., ATHERTON, J.M., and ALLISON, J.P. (1994). Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483.
36. UZENDOSKI, K., KANTOR, J.A., ABRAMS, S., SCHLOM, J., and HODGE, J.W. (1997). Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses. Hum. Gene Ther. 8, 851-860.
37. VAN LIER, R.A., POOL, M.O., KABEL, P., MOUS, S., TERPSTRA, F., DE RIE, M.A., MELIEF, C.J., and MIEDEMA, F. (1988). Anti-CD27 monoclonal antibodies identify two functionally distinct subpopulations within the CD4+ T-cell subset. Eur. J. Immunol. 18, 811-816.
38. WU, T.C., HUANG, A.Y., JAFFEE, E.M., LEVITSKY, H.L. and PARDOLL, D.M. (1995). A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182, 1415-1421.
39. YU, X., ABE, R., and HODES, R.J. (1998). The role of B7-CD28 costimulation in tumor rejection. Int. Immunol. 10, 791-797.